Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 13:7:55.
doi: 10.3389/fcimb.2017.00055. eCollection 2017.

Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options

Affiliations
Review

Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options

Chang-Ro Lee et al. Front Cell Infect Microbiol. .

Abstract

Acinetobacter baumannii is undoubtedly one of the most successful pathogens responsible for hospital-acquired nosocomial infections in the modern healthcare system. Due to the prevalence of infections and outbreaks caused by multi-drug resistant A. baumannii, few antibiotics are effective for treating infections caused by this pathogen. To overcome this problem, knowledge of the pathogenesis and antibiotic resistance mechanisms of A. baumannii is important. In this review, we summarize current studies on the virulence factors that contribute to A. baumannii pathogenesis, including porins, capsular polysaccharides, lipopolysaccharides, phospholipases, outer membrane vesicles, metal acquisition systems, and protein secretion systems. Mechanisms of antibiotic resistance of this organism, including acquirement of β-lactamases, up-regulation of multidrug efflux pumps, modification of aminoglycosides, permeability defects, and alteration of target sites, are also discussed. Lastly, novel prospective treatment options for infections caused by multi-drug resistant A. baumannii are summarized.

Keywords: Acinetobacter baumannii; antimicrobial resistance; resistance mechanism; treatment option; virulence factor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Biology of Acinetobacter baumannii. Studies of virulence factors, pathogenesis, antimicrobial resistance, treatment options of A. baumannii will provide an important aid for discovering new antibiotics and determining efficient combination therapy, which are essential strategies for combating multidrug-resistant A. baumannii infections.

Similar articles

Cited by

References

    1. Acosta J., Merino M., Viedma E., Poza M., Sanz F., Otero J. R., et al. . (2011). Multidrug-resistant Acinetobacter baumannii Harboring OXA-24 carbapenemase, Spain. Emerg. Infect Dis. 17, 1064–1067. 10.3201/eid/1706.091866. - DOI - PMC - PubMed
    1. Adams M. D., Goglin K., Molyneaux N., Hujer K. M., Lavender H., Jamison J. J., et al. . (2008). Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J. Bacteriol. 190, 8053–8064. 10.1128/JB.00834-08 - DOI - PMC - PubMed
    1. Adams M. D., Nickel G. C., Bajaksouzian S., Lavender H., Murthy A. R., Jacobs M. R., et al. . (2009). Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53, 3628–3634. 10.1128/AAC.00284-09 - DOI - PMC - PubMed
    1. Afzal-Shah M., Woodford N., Livermore D. M. (2001). Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 45, 583–588. [Epub ahead of print]. 10.1128/AAC.45.2.583-588.2001 - DOI - PMC - PubMed
    1. Al-Agamy M. H., Jeannot K., El-Mahdy T. S., Shibl A. M., Kattan W., Plesiat P., et al. . (2016). First Detection of GES-5 Carbapenemase-Producing Acinetobacter baumannii Isolate. Microb. Drug Resist. [Epub ahead of print]. 10.1089/mdr.2016.0152 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources